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The aim of this retrospective, single-centre study was to investigate the clinical and laboratory features and disease outcomes of 547
patients diagnosedwith primary Sjo¨gren’s syndrome (pSS) between 1975 and 2010.The patients were followed up for 11.4±6.2 years.
We evaluated the clinical and laboratory features, and assessed their influence on the time of diagnosis, survival, andmortality ratios,
and compared themwithin subgroups defined by gender, glandular and extraglandularmanifestations (EGMs), associated diseases,
and immunoserological abnormalities.Themost frequent EGMs were polyarthritis, Raynaud’s phenomenon, and vasculitis among
our patients; themost common associated diseasewas thyroiditis. During the follow-up period, 51 patients died; themedian survival
time was 33.71 years. Our results revealed a negative effect of cryoglobulinemia on survival ratios; additionally, the presence of
vasculitis and lymphoproliferative diseases at the time of diagnosis increased the risk of mortality. The development of vasculitis
was themost powerful predictor ofmortality.Mortality in the group of patients with extraglandular symptomswas two- to threefold
higher than in the glandular group. Attention is drawn to the importance of close monitoring and targeted diagnostic approaches
in those pSS subgroups with obviously increased mortality risk.
1. Introduction
With a prevalence of 0.2%–1.4%, primary Sjo¨gren’s syndrome
(pSS) is one of the most common chronic, slowly progressing
systemic autoimmune diseases; its main symptoms are kera-
toconjunctivitis sicca and xerostomia. The extremely various
clinical picture is characterized by multiple extraglandular
manifestations (EGMs) and associated diseases. This disease
affects predominantly middle-aged women, the gender ratio
being 9-10 to 1; however, both distributions by age and by
gender show geographical and ethnic differences [1–4].
Based on its prevalence and clinical variety, pSS is high
on the list of systemic autoimmune diseases; however, there
are only few publications on factors influencing mortal-
ity. According to the available literature data, geographical
characteristics, ethnic groups, number of patients, studied
aspects, and follow-up periods show significant differences.
The applied classification criteria (particularly in studies
performed before 2002) are not coherent in studies, making
the comparison difficult. Investigations focusing on defining
risk factors predisposing to development of lymphoprolifer-
ative diseases (LPD) are reported in several studies [5–11];
therefore, we cannot review all of them in detail.
A long-term follow-up study called attention to frequent
concomitant occurrence of LPD, glomerulonephritis, and
hypocomplementemia, as well as cutaneous vasculitis and
mixed cryoglobulinemia. The mortality was twofold higher
compared to normal population, and hypocomplementemia,
mixed cryoglobulinemia, and purpuras were considered as
adverse prognostic factors [12].
Davidson et al. emphasized the high incidence of thy-
roiditis with hypothyreosis in patients with seronegative pSS
and the role of certain serological abnormalities (antinuclear
antibody (ANA) or rheumatoid factor (RF) positivity) in
increased tendency to progression toward rheumatoid arthri-
tis (RA) or systemic lupus erythematosus (SLE). They have
confirmed that the risk for LPD is increased in pSS patients
with parotidomegaly, lymphadenomegaly, and antibody pos-
itivity to Sjo¨gren’s syndrome-specific nuclear and cytosolic
antigens (anti-SS-A/-SS-B) [13].
Hindawi Publishing Corporation
Journal of Immunology Research
Volume 2014, Article ID 647507, 8 pages
http://dx.doi.org/10.1155/2014/647507
2 Journal of Immunology Research
In a large population of pSS patients, after solid tumours,
the second most common cause of death was LPD, which
manifested before the diagnosis of pSS in 40% of cases.
An unfavourable histological finding was considered to
be the most powerful predictor of mortality, and other
listed factors included lymphadenopathy, palpable purpura,
parotidomegaly, low complement 4 (C4) levels, and positivity
for RF and ANA. The establishment of a “high-risk” or “type
I autoimmune epithelitis” risk group was recommended in
patients with parotidomegaly, palpable purpura, seropositiv-
ity for anti-SS-A or anti-SS-B, or hypocomplementemia, who
are at high risk of developing an LPD. Additionally, it has
been noted that LPD tends to develop concomitantly with
glomerulonephritis and peripheral neuropathy [14].
Studies described differences also in the geographic vari-
ation of disease. An investigation in Asia revealed that unlike
other geographical areas, the onset of pSS occurs earlier (at
30–39 years of age) in China; the percentage of patients with
systemic symptoms is significant, above 90%. The incidence
of lung and kidney involvement, pericarditis, myositis, and
pancreatitis is high, while the chance for developing Ray-
naud’s phenomenon is minimal. Thyroiditis was recorded
in one third of patients. Infections, especially pneumonia,
accounted for more than 60 percent of deaths. Mortality
caused by liver insufficiency wasmanyfold higher than that of
cardiovascular or cerebrovascular origin. Pulmonary artery
hypertension (PAH), interstitial lung disease, liver cirrhosis,
and consistently high immunoglobulin M (IgM) levels were
indicated as mortality risk factors [15].
The purpose of our retrospective study was to assess the
clinical and laboratory features and the disease outcomes of
547 pSS patients. We evaluated the influence of the main
disease features on the time of diagnosis andmortality ratios.
2. Patients and Methods
2.1. Patients. The Division of Clinical Immunology of the
University of Debrecen is one of the largest tertiary referral
centers in Hungary for systemic autoimmune diseases. In
the present study, we collected all the patients who were
diagnosed and followed up regularly with primary Sjo¨gren’s
syndrome between 1975 and 2010 at our center. From the
whole group of these 1094 patients, we gained a random
sample by using a systemic samplingmethod. After arranging
their name in alphabetical order, we selected every second
patient for the analyses. Consequently, the final population
of our retrospective study consisted of 547 (487 women and
60 men, gender ratio = 8 to 1) patients with pSS. Before
2002, Fox RI criteria [16, 17] were used for establishing the
diagnosis; after 2002, American-European consensus criteria
(AECC) were used [18]. Cases diagnosed before 2002 were
revised according to AECC. Patients were followed up every
6 months at our outpatient clinic for autoimmune diseases.
All experiments carried out in the study were in compliance
with the declaration of Helsinki.
2.2. Clinical Evaluations and Laboratory Measurements.
During follow-up visits, EGMs, associated diseases, and
immunoserological characteristics were recorded. Immuno-
serological tests were performed at the Regional Immunology
Laboratory of the University of Debrecen and included the
measurement of ANA, RF, antibodies against extractable
nuclear antigen (ENA), anti-SS-A, anti-SS-B, anti-DNA, anti-
thyroglobulin (TG), anti-thyroid peroxidase (TPO) antibody,
serum immunoglobulin, cryoglobulin, and complement lev-
els. The quantitative measurement of autoantibodies (anti-
ENA, anti-SS-A/-SS-B, anti-CCP, anti-TG, anti-TPO, ANA,
RF, and anti-DNA) was performed with enzyme-linked
immunosorbent assay (ELISA) technique. Immunoglobulin
levels and complement activity were determined with tur-
bidimetry and nephelometry techniques and haemolysis test
in sheep red blood cell suspension, respectively.The presence
of each element and its changes in time were monitored in
the whole study population. Data were evaluated by compar-
ing well-defined subgroups (women/men, glandular/EGM,
presence/absence of associated diseases, presence/absence of
immunoserological differences, and patients alive at the end
of the study/deceased over time).
2.3. Statistical Analyses. The SPSS version 20.0 (SPSS Inc.,
Chicago, IL,UDA)was used for statistical analysis. To analyze
the distribution of the data, Kolmogorov-Smirnov test was
used. In cases of normal distribution, we determined mean ±
standard deviation (SD) values and used two-sample 𝑡-test
for statistical evaluation of the experimental data. In cases of
nonnormal distribution, median, minimum, and maximum
values were calculated, and Mann-Whitney 𝑈 test was used.
Survival time and rate were assessed using Kaplan-
Meier estimator. Chi-square test and Fisher’s exact test were
used to discriminate between patient groups; we used Cox
regression model to predict poor outcome of the disease. For
comparison among patient and control groups, standardized
mortality ratios (SMRs) were calculated. Differences were
considered statistically significant at 𝑃 < 0.05.
3. Results
3.1. Patients’ Characteristics. The demographic characteris-
tics of patients’ groups are demonstrated in Tables 1 and 2.
The mean follow-up period was 11.4 ± 6.2 years with a range
from 2 to 37 years. There was no significant difference in the
mean age at the time of pSS diagnosis and in the follow-
up period between males and females. The mean age at the
time of diagnosis of the 51 deceased patients was significantly
higher than for the 496 patients still alive at the end of the
study, while there were no significant differences in follow-up
periods between the two groups. Interestingly, we statistically
confirmed that when at least one EGM was present, pSS was
diagnosed 3.5 years earlier on average than in the glandular
subgroup (Table 1). We did not observe significant difference
between the sex ratios and the presence of EGMs in patient
groups stratified by age (Table 2).
3.2. Clinical and Laboratory Features. Table 3 summarizes
the clinical manifestations and immunoserological findings
of pSS patients. The three leading EGMs each affecting
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Table 1: The mean age of patients determined at the time of diagnosis and the average follow-up period.
Subgroup Mean age at the time of diagnosis of pSS (years) Follow-up period (years)
Male (𝑛 = 60) 47.55 ± 12.051 11.47 ± 6.113
Female (𝑛 = 487) 49.99 ± 11.366 11.41 ± 6.342
𝑃 value NS NS
Alive (𝑛 = 496) 49.14 ± 11.249 11.41 ± 6.240
Deceased (𝑛 = 51; male: 5; female: 46) 55.35 ± 12.038 11.49 ± 7.035
𝑃 value <0.001 NS
EGM (𝑛 = 430) 48.97 ± 11.273 12.07 ± 6.408
Glandular (𝑛 = 117) 52.48 ± 11.751 9.04 ± 5.331
𝑃 value 0.003 <0.001
𝑃 values indicate differences between genders, alive and deceased patients, and also extraglandular and glandular subgroups.
Table 2: Percentages of sex and clinical characteristics in patient groups stratified by age.
Age at diagnosis years Patients’ number Female Male Glandular EGM
Number % Number % Number % Number %
0–29 27 23 85,19 4 14,81 6 22,22 21 77,78
30–39 70 58 82,86 12 17,14 10 14,29 60 85,71
40–49 154 136 88,31 18 11,69 26 16,88 128 83,12
50–59 183 169 92,35 14 7,65 39 21,31 144 78,69
60- 113 101 89,38 12 10,62 36 31,86 77 68,14
more than one quarter of patients were polyarthritis, Ray-
naud’s phenomenon, and vasculitis. The frequency of lym-
phadenopathy,myositis, pulmonary fibrosis, renalmanifesta-
tions, and serositis ranged between 5.3% and 9.3%.The onset
of certain EGMs (e.g., polyarthritis, Raynaud’s phenomenon,
and pulmonary fibrosis) might precede the establishment
of pSS diagnosis even with 5–9 years (Figure 1). Raynaud’s
phenomenon and serositis were manifested typically in the
early phases of the autoimmune disease; a great proportion
of cases were already present when the diagnosis of pSS is
established. Vasculitis and renalmanifestations usually devel-
oped after the diagnosis of pSS. With an incidence of 13.9%,
thyroiditis was the most common associated disease. The
occurrence of other associations (microscopic colitis, LPDs,
APS, autoimmune liver diseases, sarcoidosis, and ITP) was
lower than 4% in our study (Table 3). APS and autoimmune
liver diseases often preceded the onset of pSS, while sarcoido-
sis was characterized by latemanifestation (Figure 1).The pSS
predominantly occurred in perimenopause; additionally, in
most cases, the investigated EGMs and associated diseases
also developed in this time interval. As an exception, in some
cases (lymphadenopathy, lung fibrosis, renal manifestations,
microscopic colitis, thyroiditis, and LPDs), incidence peaked
between 40 and 49 years of age.
Approximately, 55%–75% of pSS patients were positive
for ENA, anti-SS-A, ANA, and anti-SS-B or had hypergam-
maglobulinemia. RF positivity and hypocomplementemia
occurred in more than 20% of cases, while more than 10%
of patients were anti-TPO and anti-DNA positive. Other
tested parameters (anti-TG, anti-CCP, and cryoglobulin)
were positive in 6–9 percent of cases (Table 3). Significant
gender differences were found for eight investigated fac-
tors, six of which were predominant in women (Raynaud’s
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Figure 1: Time intervals between the diagnosis of the primary
Sjo¨gren’s syndrome and the onset of extraglandular manifestations
and associated diseases.
phenomenon, thyroiditis, anti-SS-B, anti-DNA, anti-TG, and
anti-TPO) and two in men (polyarthritis, RF) (Table 3).
3.3. Disease Outcomes. During the follow-up period, 51 (46
women and 5 men) of our patients died. Mortality of the
whole patient population was almost 9 percent, with no
significant differences between genders. As to the distribution
by age groups, we lost 36 (32 female and 4 male) and 15
(14 female and 1 male) patients, from the >60 year and
40–59 year age groups, respectively. When evaluating the
causes of death, cardiovascular events (myocardial infarction,
pulmonary embolism, and stroke) were the leading causes,
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Table 3: Frequency of clinical and immunoserological features during the disease course.
Clinical and serological features Frequency (%) Distribution according to gender (𝑛) 𝑃 value
Female (𝑛 = 487) Male (𝑛 = 60)
EGMs
Polyarthritis (𝑛 = 260) 48.1 218 42 <0.001
Raynaud’s phenomenon (𝑛 = 218) 39.9 213 5 <0.001
Vasculitis (𝑛 = 137) 25 126 11 0.203
Lymphadenopathy (𝑛 = 51) 9.3 46 6 0.89
Myositis (𝑛 = 40) 6.9 35 5 0.748
Lung fibrosis (𝑛 = 34) 6.2 31 3 0.679
Renal manifestation (𝑛 = 29) 5.5 26 3 0.912
Serositis (𝑛 = 30) 5.3 29 1 0.169
Associated disorders
Thyroiditis (𝑛 = 77) 13.9 77 0 0.001
Microscopic colitis (𝑛 = 20) 3.5 17 3 0.436
LPD (𝑛 = 19) 3.3 15 4 0.152
APS (𝑛 = 15) 2.7 15 0 0.168
Autoimmune hepatitis (𝑛 = 11) 1.6 10 1 0.840
Sarcoidosis (𝑛 = 8) 1.5 6 2 0.201
ITP (𝑛 = 7) 1.3 7 0 0.350
Serological positivity
ANA (𝑛 = 353) 64.6 316 37 0.623
anti-ENA (𝑛 = 432) 78.9 382 50 0.38
anti-SS-A (𝑛 = 421) 76.9 372 49 0.359
anti-SS-B (𝑛 = 302) 55.2 277 25 0.025
anti-DNA (𝑛 = 75) 13.7 72 3 0.038
RF (𝑛 = 163) 29.8 130 33 <0.001
anti-CCP (𝑛 = 40) 7.3 34 6 0.397
anti-TG (𝑛 = 48) 8.8 48 0 0.011
anti-TPO (𝑛 = 102) 18.5 101 1 <0.001
Hypergammaglobulinemia (𝑛 = 381) 69.6 338 43 0.719
Hypocomplementemia (𝑛 = 119) 21.8 106 13 0.986
Cryoglobulinemia (𝑛 = 34) 6.2 32 2 0.567
𝑃values indicate differences between genders. LPD: lymphoproliferative disorders; APS: antiphospholipid syndrome; ITP: immune thrombocytopenic purpura;
ANA: antinuclear antibody, ENA: antibody to extractable nuclear antigen; DNA: anti-DNA antibody; RF: rheumatoid factor; TG: antibodies to thyroglobulin;
TPO: antibodies to thyroid peroxidase.
being followed by solid tumours (bronchial, colorectal, and
bladder carcinoma, as well as invasive ductal breast cancer
and malignant melanoma). Various causes (infection, ileus,
gastrointestinal bleeding, and suicide) also accounted for
some deaths. Figure 2 demonstrates the comparison of our
patients’ data and the sex- and age-adjusted data of the
general Hungarian population, based on the report of the
Hungarian Central Statistical Office from 2007 [20]. Accord-
ing to our observations, SS hardly affected the trend of cause
of death in our patient population.
Calculated mortality per 1,000 individuals per year was
as follows: in the Hungarian population adjusted for age and
gender ratios of the whole pSS population 7.821 (based on
the data of the Hungarian Central Statistical Office from
2001 [19]); in the whole pSS population 10.360; among female
patients 10.495; among male patients 9.259. Additionally,
calculated mortality per 1,000 individuals in the EGM sub-
group (11.887) was two-and-a-half-fold higher than that in
the glandular group (4.752). Standardized mortality ratios
(SMRs) were also assessed in the whole pSS population, and
separately for women and men, and for glandular and EGM
subgroups aswell (based on the data of theHungarianCentral
Statistical Office from 2001 [19]) (Table 4).
Median survival time in the whole population was
33.71 years. Patients with pSS, complicated from the time
of diagnosis with EGM or associated diseases, could be
characterized with significantly worse survival ratios. This
was also valid in the case of early occurrence of polyarthritis,
vasculitis, and LPD. Late occurrence of cryoglobulinemia
(even years after the diagnosis of pSS) also impaired survival
ratios significantly (Figures 3(a)–3(f)). In the above listed
cases, estimatedmedian survival time is obviously shortened,
compared to patients with uncomplicated pSS, at the higher
extent in the presence of LPD and vasculitis (Table 5).
Mortality risk in subgroups with significantly worse
survival ratios increased 1.085–10.716-fold. An older age at
the time of pSS diagnosis also increased the risk for death,
numerically by 8.5 percent per year.The presence of vasculitis
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Figure 2: Comparison of the causes of death between our patients’
data and the sex- and age-adjusted data on general Hungarian
population.
Table 4: Standardized mortality ratios (SMRs) of pSS subgroups.
Standardized mortality
ratios (SMRs)
Whole pSS population (𝑛 = 547) 1.32
Female patients (𝑛 = 487) 1.49
Male patients (𝑛 = 60) 0.65
Patients without EGMs (𝑛 = 117) 0.51
Patients with EGMs (𝑛 = 430) 1.62
Calculations were based on the data of the Hungarian Central Statistical
Office from 2001 [19].
before the diagnosis of pSS resulted in the highest risk, while
the lowest risk was associated with a younger age at onset of
pSS (Table 6).
4. Discussion
In our retrospective study, we reported on research out-
comes of 547 patients with pSS from one Hungarian clinical
immunology centre. No other research on pSS patients with
similar ethnical characteristics has been conducted in any
East-Central European centre before. Compared to earlier
publications, our pSS population was the third largest, but it
was the first, when considering the patient proportion related
to the whole population of the given countries [12, 14, 15].
The spectrum of our study (the number of factors potentially
influencing the clinical outcome and mortality) was broad,
investigatingmore aspects than prior studies.The value of our
observations is increased by the long follow-up period.
In Greek publications, the proportion of female patients
was high (women to men ratio = 16–22 : 1); in British and
Chinese studies it follows internationally accepted rates,
while, in Hungary, the proportion of men is higher than
usual (women to men ratio = 8 : 1). The mean age of our
patients at the time of pSS diagnosis is in line with the British
values. In Southern Europe, the disease sets on 2–5 years later,
while in China 8–10 years earlier [12–15].The influence of the
gender, the presence of EGMs and associated diseases on the
time of pSS diagnosis, and the typical time intervals for the
manifestation of clinical features were investigated only by
our working group, leading to new findings. The diagnosis
of pSS is established circa 2.5 years earlier in men, while in
the presence of at least one EGM, it is made 3.5 years earlier,
irrespective of the gender. In accordance with this finding,
it is also noted that, in women, pSS begins more often with
tolerable sicca syndromes, explaining the delayed seek for
help, while in men, a severe EGM may occur as the first
symptom.
In our study, we evaluated which EGMs and associated
diseases, in which age groups, at what typical time inter-
vals, and in what proportion occurred among our patients.
The three leading EGMs were polyarthritis, Raynaud’s phe-
nomenon, and vasculitis. The frequency of other EGMs
ranged between 5% and 10%. When comparing our results to
the literature data, we can conclude that, in the Hungarian
population, the order of frequency for EGM is similar to
what is seen in British people; the frequency of polyarthritis
and vasculitis correlates with Chinese data, while that of
Raynaud’s phenomenon and pulmonary fibrosis corresponds
to Greek data. Lymphadenopathy and renal manifestations
occurred in a lower proportion among our patients; the
incidence of myositis was higher than in the literature, while
serositis developed in an approximately similar proportion.
With few exceptions, EGMs tend to precede the onset of
systemic autoimmune disease, as if anticipating it. The newly
defined characteristic manifestation time intervals of each
EGM draw attention to the importance of cooperation with
related professions in conditions predicting pSS. Significant
gender differences were found for two EGMs: polyarthritis
with the predominance inmales and Raynaud’s phenomenon
predominating in females. The presence of EGMs enabled an
earlier establishment of the diagnosis.
During many decades of care activity, we concluded that
certain associated diseases worsen the course of pSS; there-
fore, we decided to analyse them with the method applied for
EGM. The most common associated disease in our patients
was thyroiditis, while incidence of other associated diseases
was below 3%-4% [21]. When comparing the frequency
of associated disease with the few available literature data,
the following can be concluded. The percent incidence of
thyroiditis in the Hungarian and British population [13] was
approximately the same, and in Chinese people [15] it was
more than twofold as compared to Hungarians, while in
the Greek population no such investigation was performed.
The incidence of LPD in Hungarian pSS patients was in line
with Greek values, in British people it was 1 percent, and it
was not measured for the Chinese population. Autoimmune
liver diseases occurred half as frequently in our patients,
when compared to Greek, British, and Chinese data. The
risk group and the screening tests for autoimmune liver
6 Journal of Immunology Research
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Figure 3: The Kaplan-Meier survival plots for the risk of death in patients subgroups with/without (a) extraglandular manifestations, (b)
polyarthritis, (c) vasculitis, (d) associated disorders and (e) lymphoproliferative disease developed already at the time of diagnosis, or (f)
cryoglobulinemia developed during the disease course.
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Table 5: Variations in survival times for parameters that are significantly impairing survival indicators compared to the average values of
patients.
𝑃 value, when a
certain factor is
present at the time of
pSS diagnosis
𝑃 value, when a
certain factor
manifests after the
diagnosis of the pSS
Survival time (year) CI 95%
Mean survival time for our patient with pSS 33.71
Studied factor
EGM 0.001 NS 26.949 23.907–29.991
Polyarthritis <0.001 NS 27.554 23.844–31.263
Vasculitis <0.001 NS 7.956 6.700–9.213
Associated disorder <0.001 NS 14.283 10.962–17.603
LPD <0.001 NS 4.000 4.000-4.000
Cryoglobulinemia NS 0.010 24.112 19.899–28.326
CI: confidence interval; NS: nonsignificant.
Table 6: Mortality risk in subgroups with significantly worse
survival indicators, also taking into consideration the age recorded
at the diagnosis.
Analysed variable 𝑃 value Relative risk CI 95%
Age at the diagnosis of pSS
(continuous variable) <0.001 1.085
∗ 1.049–1.121
Polyarthritis 0.048 1.898 1.006–3.581
Vasculitis 0.001 10.716 2.795–41.089
LPD 0.005 5.172 1.652–16.192
Cryoglobulinemia 0.038 2.331 1.048–5.185
∗With one year increase in age the risk for death is 1.085-fold higher.
diseases have been defined by our working group in pSS
previously [22]. Apart from our working group, APS was
evaluated only by Chinese researchers [15], who found a two-
to threefold higher prevalence compared to the Hungarian
population. Our data regarding association with microscopic
colitis, sarcoidosis, and ITP appear for the first time in the
literature. The chronic low-grade inflammation typical for
pSS might cause the remodeling of gut wall which explains
the associationwithmicroscopic colitis, as ourworking group
published in 2005 [23].
Differences in the prevalence of EGMs and associated
diseases modifying the clinical picture, as compared to
literature data, may be explained by the influence of dif-
ferent genetic, life style, and geographical factors. In 2002,
we reviewed non-Hodgkin’s lymphoma (NHL) patients to
describe its coexistence with autoimmune diseases.Themost
frequent autoimmunedisease in theNHLgroupwas pSS.This
association can be explained by the dysregulation of apoptosis
and increased levels of activated B-cells [24]. Our results
regarding the distribution of associated diseases by gender
and age group and their influence on survival and mortality
ratios are new, and no similar analysis has been performed
earlier.
Significant gender differences were found for several
serological factors. Anti-TG and anti-TPO positivity pre-
vailed in females, while RF showed male predominance, in
accordance with the observed clinical differences, and with
the dominance of thyroiditis in women and polyarthritis in
men. Cryoglobulinemia can be considered a highly relevant
immunoserological abnormality, the emergence of which in
the follow-up period of pSS significantly impairs survival
ratios and increasesmortality risk. In our previous reports, we
concluded that cryoglobulinemia may play a more important
role in the extraglandular features observed in SS associated
with hepatitis C virus (HCV) than it does in pSS alone,
although these manifestations also might be related to either
the underlying SS or the HCV infection itself [25, 26]. Inter-
estingly, the mortality of the whole patient population was
comparable to that of normal Hungarian population, demon-
strating the adequacy of care and a relatively favourable
course of the disease.
5. Conclusion
Summarizing our results, we concluded that pSS is com-
posed of subgroups displaying a different clinical picture
and mortality risk. During our work, we identified clinical
and immunoserological features characterizing Hungarian
patients. Based on significantly worse survival ratios and the
concomitantly increasing mortality risk, pSS subgroups with
polyarthritis, vasculitis, LPD, or cryoglobulinemia should be
clinically classified as severe pSS. Consequently, we recom-
mend the use of targeted diagnostic protocols for identifying
patients with severe pSS.Moreover, close observation of cases
associated with polyarthritis, vasculitis, LPDs, or cryoglobu-
linemia is also essential.
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